Clinical Trial Detail

NCT ID NCT02142868
Title Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
Recruitment No longer available
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Pfizer
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole + Palbociclib

Age Groups: adult

Additional content available in CKB BOOST